Healthcare, Pharma & Life Sciences

Tang Prize Honors CAR-T Pioneers Rosenberg, Sadelain, June in Taipei

Image
Tang Prize Honors CAR-T Pioneers Rosenberg, Sadelain, June in Taipei

Taipei – September 20, 2026 -- The 2026 Tang Prize Award Ceremony convened in Taipei on September 18, honoring six laureates across four categories including three scientists whose work led to FDA-approved CAR T-cell cancer therapies now used worldwide.

Three biopharmaceutical laureates trace a four-decade path from lab discovery to approved cancer drugs

Dr. Steven A. Rosenberg, who joined remotely, cited his team's work four decades ago showing that tumor-infiltrating lymphocytes (TILs) taken from patients' own tumors could drive cancer regression, establishing the concept of a patient's lymphocytes as a 'living drug.' That research laid groundwork for later T cell receptor (TCR) and chimeric antigen receptor (CAR) therapeutic strategies now deployed clinically.

mAbxience, Sandoz Partner on Emicizumab Biosimilar for Hemophilia A

Image
mAbxience, Sandoz Partner on Emicizumab Biosimilar for Hemophilia A

Madrid – September 20, 2026 -- mAbxience and Sandoz have signed a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar targeting hemophilia A, a treatment referencing Roche's Hemlibra with an estimated global reference market of USD 5.7 billion.

mAbxience will develop and manufacture the biosimilar at GMP facilities in Spain and Argentina

Under the agreement, mAbxience is responsible for development and manufacturing through its facilities in the two countries. Sandoz will handle global commercialization.

Sandoz secures exclusive global rights excluding three South American markets

Sandoz holds exclusive commercialization rights worldwide, with the exception of Argentina, Uruguay and Paraguay. Financial terms of the deal were not disclosed.

ACROBiosystems Opens France Hub at Villejuif Life Sciences Campus

Zurich – September 20, 2026 -- ACROBiosystems has established a dedicated office within The HIVE Innovation Center on Campus Grand Parc in Villejuif, deepening its footprint in France's oncology research corridor. The move, facilitated by real estate operator Kadans Science Partner, gives the roughly 1,000-employee biotechnology group direct proximity to biotechs, hospitals, and translational research institutes clustered around Paris-Saclay.

ACROBiosystems joins a biocluster it entered as a member last year

The company became a member of the Paris-Saclay Cancer Cluster (PSCC) in 2025, and the new HIVE office is positioned to extend those regional ties. Campus Grand Parc concentrates oncology-focused clinical partners and research teams, an environment ACROBiosystems says aligns with its role supplying reagents and services across the drug development chain -- from recombinant proteins and antibodies to GMP-grade custom production.

MyPureSkin Named Among 2026's Top 20 Innovative Healthcare Firms

London – September 20, 2026 -- Business Worldwide Magazine has named MyPureSkin S.A, a Swiss nutricosmetics company, to its list of the 20 Most Innovative Healthcare Companies to Watch in 2026.

Swiss firm builds clinically validated skin-health platform from Health Valley base

Founded by Edgar Brandt and Tatiana Brandt in Switzerland's Health Valley, MyPureSkin operates on the premise that skin should receive the same nutritional and scientific attention as other organs. The company now sells across Europe, North America, the Middle East, and Australia.

Proprietary Nutrigevity framework anchors product development

MyPureSkin's formulations are built around NutrigevityTM, a proprietary framework targeting three biological pillars: Structure, Signalling, and Regeneration. The framework draws on expertise from clinical medicine, plastic surgery, gynaecology, micronutrition, and skin biology.

Apollo Athenaa Treats 30,000 Women, Marks 1,000+ Cancer Surgeries in Year One

Image
Apollo Athenaa Treats 30,000 Women, Marks 1,000+ Cancer Surgeries in Year One

New Delhi – September 20, 2026 -- Apollo Athenaa Women's Cancer Centre has treated more than 30,000 women from over 110 cities and performed 1,000-plus cancer surgeries in its first year of operation, marking its anniversary as Asia's first dedicated cancer centre for women.

Centre completes 4,000+ chemotherapy cycles and 100+ reconstruction procedures in year one

Apollo Athenaa's clinical volumes in its debut year include over 4,000 chemotherapy cycles, more than 100 plastic and breast reconstruction procedures, and 120-plus VABB (vacuum-assisted breast biopsy) procedures. The centre built an integrated care model spanning breast and gynaecological oncology, reconstruction, medical and precision oncology, diagnostics and rehabilitation.

Halozyme Prices Upsized $1.3 Billion Convertible Notes Due 2033

Image
Halozyme Prices Upsized $1.3 Billion Convertible Notes Due 2033

San Diego – September 20, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) priced $1.3 billion in convertible senior notes due 2033, upsized from an initially announced $1.05 billion offering, carrying a 1.50% annual coupon.

Halozyme secures $1.275 billion in net proceeds from the notes sale

The San Diego-based biopharmaceutical company said net proceeds from the offering total approximately $1.275 billion, rising to $1.471 billion if initial purchasers fully exercise a 13-day option to buy an additional $200 million in notes. The notes, sold to qualified institutional buyers under Rule 144A, carry an initial conversion price of approximately $139.84 per share, a 27.5% premium over Halozyme's September 20, 2026 closing price of $109.68. The notes mature September 20, 2026, with closing expected September 20, 2026.

ISEA Adds Naloxone to Workplace First Aid Standard Z308.1

Arlington, Va. – September 20, 2026 -- The International Safety Equipment Association (ISEA) has released ANSI/ISEA Z308.1-2026, the sixth revision of the American National Standard for workplace first aid kits, now recommending naloxone as a standard supply amid rising opioid-related deaths on the job.

Overdose deaths now account for nearly 10% of workplace fatalities

Fatal overdoses represent close to 10 percent of workplace deaths, yet only 28 percent of employers report being fully stocked with naloxone at worksites, according to a National Safety Council survey cited by ISEA. CDC data show more than 80,000 drug overdose deaths in 2024, with opioids involved in the majority of cases.

Otsuka ICU Medical Recalls Saline Bags Mislabeled as Potassium Chloride

Image
Otsuka ICU Medical Recalls Saline Bags Mislabeled as Potassium Chloride

Austin, Texas – – September 20, 2026 -- Otsuka ICU Medical LLC has issued a voluntary user-level recall of one lot of 0.9% Sodium Chloride Injection, USP, 100 mL, after discovering that bags labeled as saline may actually contain highly concentrated Potassium Chloride Injection.

Mislabeled overwrap conceals lethal potassium concentrate inside saline packaging

The affected lot, NDC 0990-7984-23, Lot 1042188, carries external labeling identifying it as 0.9% Sodium Chloride Injection, USP. Internally, however, the overwrap may instead contain Potassium Chloride Inj. 10 mEq (NDC 0990-7074-26, Lot 1035181), a highly concentrated formulation intended for diluted use only.

New Analysis: Skin Cancer Cases 40% Higher Than Reported Estimate

Image
New Analysis: Skin Cancer Cases 40% Higher Than Reported Estimate

Burr Ridge, Ill. – September 20, 2026 -- SkinCure Oncology reported that 4.7 million Americans are diagnosed with nonmelanoma skin cancer (NMSC) annually, a figure more than 40 percent higher than the widely cited benchmark of 3.3 million patients that has anchored healthcare policy discussions for over a decade.

Updated analysis replaces a 14-year-old dataset

The long-standing statistic of 3.3 million Americans diagnosed with 5.4 million NMSC lesions annually stems from a 2015 study built on 2012 data. SkinCure Oncology's new benchmark puts annual lesion counts at 6.7 to 7.7 million, reflecting the disease's disproportionate impact on aging populations.

Valley Oaks Health Wins $828,375 Rural Grant for Indiana Care

Image
Valley Oaks Health Wins $828,375 Rural Grant for Indiana Care

Lafayette, Ind. – September 20, 2026 -- Valley Oaks Health has secured $828,375 through the Growing Rural Opportunities for Well-being (GROW) Region 3 Grant to expand integrated healthcare access across rural northwest central Indiana.

Funding stems from a $206.9 million federal transformation program

The award is part of the Indiana Rural Health Transformation Program (Indiana RHTP), a statewide initiative fully funded by the Centers for Medicare & Medicaid Services (CMS) under a financial assistance award totaling $206,927,896.80. CMS/HHS covers 100 percent of the program, which spans five years and targets healthcare infrastructure, workforce development, and regional collaboration.